Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | DHPS | P49366 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5808991 | 0.85 | GRM5 (0.39) | HTTKCNJ1GRM5 | |
| SCHEMBL5811735 | 0.81 | PARP10 (0.41) | HTTMEN1KMT2AMAPTDHPS | |
| SCHEMBL5809501 | 0.79 | HTT (0.54) | HTTMEN1KMT2AMAPTDHPS | |
| SCHEMBL5808818 | 0.78 | GRM5 (0.40) | HTTMEN1KMT2AMAPTDHPS | |
| SCHEMBL5809369 | 0.77 | POLB (0.48) | HTTMEN1KMT2APOLBRECQL | |
| SCHEMBL5810873 | 0.77 | HTT (0.43) | HTTMEN1KMT2AMAPTDHPS | |
| SCHEMBL5806592 | 0.75 | ALDH1A1 (0.49) | HTTMEN1KMT2AMAPTGRM5 | |
| SCHEMBL12059947 | 0.74 | ALOX15 (0.43) | MEN1KMT2AMAPTITGB3ITGA2B | |
| SCHEMBL5808795 | 0.73 | MRGPRX4 (0.37) | HTTMEN1KMT2AMAPTDHPS | |
| SCHEMBL5810628 | 0.71 | DRD2 (0.43) | HTTMEN1KMT2AMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144894-B2 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| US-20060063799-A1 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063799-A1 | Sulfonamide bicyclic compounds | APP, BACE1, IAPP | HTT 242/4885MEN1 2317/4885KMT2A 4130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.